Clinical trials: Alzheimer Disease 4
Vaccine Response
Study of Safety and Immunogenicity of HIV Vaccines in Healthy Volunteers
Background: Vaccines create resistance to disease. This study tests experimental human immunodeficiency virus (HIV) vaccines that use an adenovirus as a transporter.
- Trial name
- NCT01989533
- Testing
- Ad4-mgag, Ad4-EnvC150, gp 120 Protein Boost
- Where
- United States
- Volunteers
- 62 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Alzheimer´s Disease
Safety Study of a Glycogen Synthase Kinase 3 (GSK3) Inhibitor in Patients With Alzheimer´s Disease
The purpose of this study is to evaluate if 4 escalating doses during 20 weeks of NP031112 are safe and tolerated in patients with Alzheimer´s disease.
- Trial name
- NCT00948259
- Testing
- NP031112
- Where
- 3 sites in Germany
- Volunteers
- 30 people
- Sponsor
- Noscira SA
Mild to Moderate Alzheimer's Disease
4 Week, Safety and Tolerability Study in Patients With Mild to Moderate Alzheimer's Disease
The primary purpose of the study is to determine the safety and tolerability of AZD1446 vs Placebo given as an add-on treatment to Donepezil for 4 weeks in patients with mild to moderate Alzheimer's disease.
- Trial name
- ROBIN (NCT01039701)
- Testing
- AZD1446
- Where
- 12 sites in Czechia, Hungary and 1 more
- Volunteers
- 99 people
- Sponsor
- AstraZeneca
Alzheimer Disease
A Phase 3 Study of Rotigotine in Combination with Rivastigmine in Mild to Moderate Alzheimer's Disease
This is a 24-week prospective, randomized, double-blind, placebo-controlled, multi-center phase III study evaluating efficacy and safety of rotigotine 4mg/24 hrs in combination with rivastigmine 9.5 mg/24 hrs in mild to moderate…
- Trial name
- DOPAD-3 (NCT06702124)
- Testing
- Rotigotine 4Mg/24Hrs Patch
- Where
- Italy
- Volunteers
- 348 people
- Sponsor
- I.R.C.C.S. Fondazione Santa Lucia
Healthy Volunteer
Intranasal AD4-H5-VTN as an Adenovirus Vaccine
Background: Adenoviruses are viruses that typically cause symptoms of a cold or eye infection. These viruses are being tested as part of a possible new vaccine.
- Trial name
- NCT01806909
- Testing
- Ad4-H5-Vtn
- Where
- United States
- Volunteers
- 51 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Alzheimer Disease
Study Evaluating the Safety and Efficacy of Bapineuzumab in Alzheimer Disease Patients
This is a study to evaluate the efficacy and safety of multiple doses of bapineuzumab in patients with mild to moderate Alzheimer Disease. Patients will receive either bapineuzumab or placebo.
- Trial name
- NCT00676143
- Testing
- bapineuzumab
- Where
- 288 sites in United States, Argentina and 22 more
- Volunteers
- 1,100 people
- Sponsor
- Pfizer
Mild Cognitive Impairment (MCI), Subjective Memory Complaint
Validation of a Digital Intervention to Rehabilitate Cognitive Resources
The goal of this clinical trial is to learn if the use of a digital cognitive rehabilitation system named RICORDO, that is flexible and capable of adapting the rehabilitation pathway according to the needs and capacity of the…
- Conditions
- Mild Cognitive Impairment (MCI), Subjective Memory Complaint, Dementia Alzheimer Type
- Trial name
- MI-RICORDO (NCT07064226)
- Testing
- RICORDO, Treatment as Usual (TAU)
- Where
- Italy
- Volunteers
- 102 people
- Sponsor
- Fondazione Don Carlo Gnocchi ETS
HIV
Clinical Trial to Evaluate the Safety, Tolerability, and Immunogenicity of 16055 NFL Delta Gly4 Env Protein Trimer and Trimer 4571 Combined With 3M-052-AF + Alum Adjuvant and Ad4-Env145NFL Viral Particles as Heterologous Prime-boost Regimens in Adult Participants Without HIV.
The goal of this clinical trial is to test 16055 NFL delta Gly4 Env protein trimer and Trimer 4571 combined with 3M-052-AF + Alum adjuvant and Ad4-Env145NFL viral particles as heterologous prime-boost regimens in adult…
- Trial name
- NCT06332339
- Testing
- 16055 NFL delta Gly4 trimer, Trimer 4571, Ad4-Env145NFL, 5 x 108 viral particles (vp)
- Where
- 6 sites in United States
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Alzheimer's Disease
Study Investigating the Effects of JNJ-54861911 on Amyloid-beta Processing in Cerebrospinal Fluid (CSF) and Plasma in Japanese Participants Asymptomatic at Risk for Alzheimer Dementia
The purpose of this study is to determine the safety, tolerability and effect of JNJ-54861911 on level of amyloid-beta in Cerebrospinal Fluid (CSF) and plasma following 4 weeks of treatment in Japanese participants asymptomatic…
- Trial name
- NCT02360657
- Testing
- JNJ-54861911, 10 mg, JNJ-54861911, 50 mg
- Where
- 2 sites in Japan
- Volunteers
- 18 people
- Sponsor
- Janssen Pharmaceutical K.K.
Family, Dementia
Evaluation of "My Tools 4 Care" for Family Caregivers of Persons With Dementia
With the number of Canadians with Alzheimer's disease and related dementias (ADRD) growing, supporting family care partners of persons with ADRD is critical.
- Trial name
- NCT02428387
- Testing
- My Tools 4 Care
- Where
- 2 sites in Canada
- Volunteers
- 199 people, healthy volunteers welcome
- Sponsor
- University of Alberta
Anthrax Infection
A Phase 1 Ascending Dose Study to Assess the Safety and Immunogenicity of Adenovirus Anthrax Vector Candidate Vaccines
The purpose of this study is to evaluate 2 vaccine candidates against anthrax compared to the positive (vaccine) control as studied in normal healthy volunteers.
- Trial name
- NCT01979406
- Testing
- AVA, Ad4-PA-1, Ad4-PA-GPI-1
- Where
- 4 sites in United States
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Emergent BioSolutions
Alzheimer Disease
A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease
The main purpose of this study is to assess how well Donanemab is tolerated and what side effects may occur in Indian participants with early symptoms of Alzheimer's Disease (AD).
- Trial name
- NCT07838155
- Testing
- Donanemab
- Where
- 12 sites in India
- Volunteers
- 50 people
- Sponsor
- Eli Lilly and Company
Alzheimer's Disease, Healthy
Relative Bioavailability Study of Four Experimental Formulations for Alzheimer's Disease
The purpose of this study is to assess the bioavailability of four experimental formulations relative to the current reference formulation used in the Phase 2 study.
- Trial name
- NCT00901498
- Testing
- BMS-708163
- Where
- United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Bird Flu, Influenza
Safety and Immunogenicity of Replication-Competent Adenovirus 4-vectored Vaccine for Avian Influenza H5N1
The purpose of this study is to compare the safety and immunogenicity over a 9-month period of five different dosages of Ad4-H5-Vtn in volunteers (Vaccinees) who receive three doses of the study vaccine or placebo.
- Trial name
- NCT01006798
- Testing
- Ad4-H5-Vtn, Sanofi Pasteur Influenza Virus Vaccine, H5N1
- Where
- 4 sites in United States
- Volunteers
- 166 people, healthy volunteers welcome
- Sponsor
- Emergent BioSolutions
Alzheimer's Disease
Thalidomide for Patients With Mild to Moderate Alzheimer's Disease
This is a 24-week, randomized, double-blind, placebo-controlled study of the effect of thalidomide and placebo on CSF (cerebral spinal fluid) and plasma biomarkers in patients with mild to moderate Alzheimer's disease.
- Trial name
- NCT01094340
- Testing
- Thalidomide
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Banner Health
Alzheimer's Disease
Efficacy, Safety and Tolerability of Tideglusib to Treat Mild-to-Moderate Alzheimer's Disease Patients
The main purpose of this study is to evaluate the cognitive changes after administration of tideglusib versus placebo at two oral doses and two treatment regimes for 26 weeks in patients with mild to moderate Alzheimer's disease.
- Trial name
- ARGO (NCT01350362)
- Testing
- tideglusib
- Where
- 6 sites in Belgium, Finland and 4 more
- Volunteers
- 306 people
- Sponsor
- Noscira SA
Alzheimer's Disease
Alzheimer's Disease Reminiscence Quality of Life
The effectiveness of reminiscence for dementia has been claimed as an effective tool, but scientific validation and systematic assessment of this method is needed.
- Trial name
- NCT01295957
- Testing
- reminiscence therapy, comparison group, control
- Where
- Argentina
- Volunteers
- 135 people, healthy volunteers welcome
- Sponsor
- Universidad Nacional de Rosario
Healthy, Adult
Study Evaluating Effects of SAM-531 on Sleep Electroencephalogram (EEG) and Quantitative Wake EEG in Healthy Subjects
Primary: To evaluate the pharmacologic effect of single doses of SAM-531 on sleep EEG in healthy subjects.
- Trial name
- NCT00519298
- Testing
- SAM-531, Donepezil
- Where
- France
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Alzheimer Disease
A Study of Zunveyl on Safety, Tolerability, Neuropsychiatric Symptoms, and Caregiver Distress in Alzheimer's Disease (RESOLVE)
The primary purpose of this study is to evaluate the safety and tolerability of Zunveyl® over 12 weeks of routine clinical use in adults with mild to moderate Alzheimer's disease.
- Trial name
- RESOLVE (NCT07633470)
- Testing
- Zunveyl®
- Where
- 22 sites in United States
- Volunteers
- 150 people
- Sponsor
- Alpha Cognition, Inc
Alzheimer Disease
Effect on the Electrocardiographic QT Interval Corrected for Heart Rate (QTc) in Healthy Subjects
The purpose of this study is to determine the effect of BMS-708163 on the QTc interval (QT interval corrected for heart rate).
- Trial name
- NCT00979316
- Testing
- BMS-708163, Moxifloxacin
- Where
- United States
- Volunteers
- 62 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb